// App-Quantinova.ai

629 : Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?

Researchers

Presenter

  • Suneil Kapur

Principal Investigators

  • Proton Rahman

  • Michelle Teo

  • Jodie Reis

  • Rajwinder Dhillon

  • Pauline Boulos

  • Raman Rai

  • Regan Arendse

  • Julie Vaillancourt

  • Emmanouil Rampakakis

  • Allen J Lehman

  • Francois Nantel

  • Brendan Osborne

Medical Centers

  • University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada

  • Rheumatology, St. Clar-s Mercy Hospital, St. John's, NF, Canada

  • Balfour Medical Clinic, Penticton, BC, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Private Practice, Niagara Falls, ON, Canada

  • Private Practice, Dundas, ON, Canada

  • Private Practice, Burlington, ON, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • JSS Medical Research, Montreal, QC, Canada

  • Janssen Inc., Toronto, ON, Canada

  • Medical Affairs, Janssen Inc., Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Ustekinumab

  • Infliximab

  • golimumab

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved